Contribute Try STAT+ Today

While prescriptions for antidepressants have climbed in the U.S. in recent years, those for anxiety and insomnia have fallen, a new report shows — but the numbers also suggest the coronavirus pandemic could fuel a rise in the use of medications for all three conditions.

A new report from pharmacy benefits manager Express Scripts finds that prescriptions for medications used to treat depression, anxiety, and other mental health conditions are climbing. The findings come from an analysis of weekly prescription data from 2015 to 2019. One important caveat of the data, which draws from pharmacy claims data from 3.4 million privately-insured people in the U.S., is that it does not include information on people on public insurance, who generally face a higher burden of mental illness.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.